Autopsy report · NCT04762901

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

“Funding was terminated.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Wake Forest University Health Sciences

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Niraparib; Doxorubicin; Cyclophosphamide; Paclitaxel; Pegfilgrastim; Carboplatin

Participants

0

Trials that died the same way

• Vancomycin for Primary Sclerosing Cholangitis
  “Funding terminated” (93% match in meaning)
• Mindfulness Intervention for Caregivers of Autism in Rural Environments
  “Funding was terminated, seeing new funding.” (91% match in meaning)
• Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
  “Souces of funding have been terminated” (88% match in meaning)
• Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery
  “Funding terminated by funding source.” (87% match in meaning)
• Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
  “Terminated due to loss of funding” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.